📰 Functional Improvement News
Functional Improvement News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Functional Improvement. Real-time updates on events, politics, business and more.
May 20, 2024
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - - DYNE-101 Showed Improvement in Myotonia,...
May 20, 2024
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - ...
April 4, 2024
Researchers explored using Erigeron breviscapus (EB) as a treatment for osteoarthritis (OA).
November 16, 2023
News and analytical articles about Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan.
November 13, 2023
- Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease...
September 21, 2023
News and analytical articles about Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan.
March 16, 2023
/PRNewswire/ -- WHAT: Innovative therapeutic approaches for left ventricular restoration for patients with Heart Failure with Reduced Ejection Fraction (HFrEF)....
March 25, 2022
Equities analysts forecast that Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) will post earnings of ($0.93) per share for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Cytokinetics’ earnings. The highest EPS estimate is ($0.75) and the lowest is ($1.02). Cytokinetics reported earnings of ($0.66) per share during the same […]
March 15, 2022
Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) have earned a consensus recommendation of “Buy” from the fifteen analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and twelve have given a buy recommendation to the company. […]
March 14, 2022
Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) have been assigned a consensus recommendation of “Buy” from the fifteen ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and twelve have given a buy rating to the company. […]